Home >> Research Area >>Others>>Renin>> VTP-27999 2,2,2-trifluoroacetate

VTP-27999 2,2,2-trifluoroacetate

Topo II inhibitor CAS# 1013937-63-7

VTP-27999 2,2,2-trifluoroacetate

Catalog No. BCC2049----Order now to get a substantial discount!

Product Name & Size Price Stock
VTP-27999 2,2,2-trifluoroacetate: 5mg $437 In Stock
VTP-27999 2,2,2-trifluoroacetate: 10mg Please Inquire In Stock
VTP-27999 2,2,2-trifluoroacetate: 20mg Please Inquire Please Inquire
VTP-27999 2,2,2-trifluoroacetate: 50mg Please Inquire Please Inquire
VTP-27999 2,2,2-trifluoroacetate: 100mg Please Inquire Please Inquire
VTP-27999 2,2,2-trifluoroacetate: 200mg Please Inquire Please Inquire
VTP-27999 2,2,2-trifluoroacetate: 500mg Please Inquire Please Inquire
VTP-27999 2,2,2-trifluoroacetate: 1000mg Please Inquire Please Inquire
Related Products

Quality Control of VTP-27999 2,2,2-trifluoroacetate

Number of papers citing our products

Chemical structure

VTP-27999 2,2,2-trifluoroacetate

3D structure

Chemical Properties of VTP-27999 2,2,2-trifluoroacetate

Cas No. 1013937-63-7 SDF Download SDF
PubChem ID 66577057 Appearance Powder
Formula C28H42ClF3N4O7 M.Wt 639.1
Type of Compound N/A Storage Desiccate at -20°C
Synonyms VTP-27999
Solubility H2O : 10 mg/mL (15.65 mM; Need ultrasonic)
Chemical Name methyl N-[2-[(3-chlorophenyl)-[(3R)-1-[[(2S)-2-(methylamino)-3-[(3R)-oxan-3-yl]propyl]carbamoyl]piperidin-3-yl]methoxy]ethyl]carbamate;2,2,2-trifluoroacetic acid
SMILES CNC(CC1CCCOC1)CNC(=O)N2CCCC(C2)C(C3=CC(=CC=C3)Cl)OCCNC(=O)OC.C(=O)(C(F)(F)F)O
Standard InChIKey SYWYSVAEGXHOJO-WHTVDMENSA-N
Standard InChI InChI=1S/C26H41ClN4O5.C2HF3O2/c1-28-23(14-19-6-5-12-35-18-19)16-30-25(32)31-11-4-8-21(17-31)24(20-7-3-9-22(27)15-20)36-13-10-29-26(33)34-2;3-2(4,5)1(6)7/h3,7,9,15,19,21,23-24,28H,4-6,8,10-14,16-18H2,1-2H3,(H,29,33)(H,30,32);(H,6,7)/t19-,21-,23+,24?;/m1./s1
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months.
Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it.
About Packaging 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial.
2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial.
3. Try to avoid loss or contamination during the experiment.
Shipping Condition Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request.

Biological Activity of VTP-27999 2,2,2-trifluoroacetate

DescriptionHighly potent and selective renin inhibitor (IC50 = 0.47 nM). Displays >1000-fold selectivity over related and unrelated off-targets. Blocks renin-stimulated ERK1/2 phosphorylation in vascular smooth muscle cells. Exhibits a different mode of action to aliskiren.

VTP-27999 2,2,2-trifluoroacetate Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

VTP-27999 2,2,2-trifluoroacetate Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Preparing Stock Solutions of VTP-27999 2,2,2-trifluoroacetate

1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 1.5647 mL 7.8235 mL 15.647 mL 31.294 mL 39.1175 mL
5 mM 0.3129 mL 1.5647 mL 3.1294 mL 6.2588 mL 7.8235 mL
10 mM 0.1565 mL 0.7824 mL 1.5647 mL 3.1294 mL 3.9118 mL
50 mM 0.0313 mL 0.1565 mL 0.3129 mL 0.6259 mL 0.7824 mL
100 mM 0.0156 mL 0.0782 mL 0.1565 mL 0.3129 mL 0.3912 mL
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations.

Organizitions Citing Our Products recently

 
 
 

Calcutta University

University of Minnesota

University of Maryland School of Medicine

University of Illinois at Chicago

The Ohio State University

University of Zurich

Harvard University

Colorado State University

Auburn University

Yale University

Worcester Polytechnic Institute

Washington State University

Stanford University

University of Leipzig

Universidade da Beira Interior

The Institute of Cancer Research

Heidelberg University

University of Amsterdam

University of Auckland
TsingHua University
TsingHua University
The University of Michigan
The University of Michigan
Miami University
Miami University
DRURY University
DRURY University
Jilin University
Jilin University
Fudan University
Fudan University
Wuhan University
Wuhan University
Sun Yat-sen University
Sun Yat-sen University
Universite de Paris
Universite de Paris
Deemed University
Deemed University
Auckland University
Auckland University
The University of Tokyo
The University of Tokyo
Korea University
Korea University

Background on VTP-27999 2,2,2-trifluoroacetate

VTP-27999, 2,2,2-trifluoroacetate (1:1) is useful for Hypertension and End-Organ Diseases.

Featured Products
New Products
 

References on VTP-27999 2,2,2-trifluoroacetate

Renin inhibitor VTP-27999 differs from aliskiren: focus on their intracellular accumulation and the (pro)renin receptor.[Pubmed:24637873]

J Hypertens. 2014 Jun;32(6):1255-63.

BACKGROUND: VTP-27999 is a renin inhibitor with an IC50 that is comparable to that of aliskiren, but with a higher bioavailability. Unexpectedly, VTP-27999, unlike aliskiren, did not unfold renin's precursor, prorenin, and increased the affinity of the antibodies applied in renin immunoassays. METHODS: Here we verified to what degree these differences affect intracellular renin inhibitor accumulation in renin-synthesizing human mast cells (HMC-1), and (pro)renin's signaling via the (pro)renin receptor ((P)RR) in rat vascular smooth muscle cells. We also addressed the consequences of (P)RR knockdown by small-interfering (si) RNA on (pro)renin release. Finally, making use of FRET(Bodipy-FL)-labeled aliskiren, we studied, by subcellular fractionation, the cellular distribution pattern of this renin inhibitor. RESULTS: VTP-27999 accumulated at higher levels in HMC-1 cells than aliskiren, allowing this inhibitor to block intracellular renin at approximately five-fold lower medium levels. Labeled aliskiren accumulated in mitochondria and lysosomes, and its distribution pattern was different from that of renin. Moreover, the intracellular accumulation of both inhibitors in nonrenin-synthesizing HEK293 cells was not different from that in HMC-1 cells, suggesting that it is renin synthesis-independent. VTP-27999, but not aliskiren, blocked renin's capacity to stimulate extracellular signal-regulated kinase 1/2 phosphorylation in vascular smooth muscle cells, whereas neither inhibitor interfered with prorenin-induced signaling. (P)RR knockdown greatly increased renin (and to a lesser degree, prorenin) release, without affecting the capacity of forskolin or cAMP to stimulate renin release. CONCLUSION: VTP-27999 differs from aliskiren regarding its level of intracellular accumulation and its capacity to interfere with renin signaling via the (P)RR, and the (P)RR determines prorenin-renin conversion and constitutive (but not regulated) (pro)renin release.

Discovery of VTP-27999, an Alkyl Amine Renin Inhibitor with Potential for Clinical Utility.[Pubmed:24900262]

ACS Med Chem Lett. 2011 Aug 9;2(10):747-51.

Structure guided optimization of a series of nonpeptidic alkyl amine renin inhibitors allowed the rational incorporation of additional polar functionality. Replacement of the cyclohexylmethyl group occupying the S1 pocket with a (R)-(tetrahydropyran-3-yl)methyl group and utilization of a different attachment point led to the identification of clinical candidate 9. This compound demonstrated excellent selectivity over related and unrelated off-targets, >15% oral bioavailability in three species, oral efficacy in a double transgenic rat model of hypertension, and good exposure in humans.

Description

VTP-27999 TFA is an alkyl amine Renin inhibitor; VTP-27999 TFA is useful for Hypertension and End-Organ Diseases.

Keywords:

VTP-27999 2,2,2-trifluoroacetate,1013937-63-7,VTP-27999,Natural Products,Renin, buy VTP-27999 2,2,2-trifluoroacetate , VTP-27999 2,2,2-trifluoroacetate supplier , purchase VTP-27999 2,2,2-trifluoroacetate , VTP-27999 2,2,2-trifluoroacetate cost , VTP-27999 2,2,2-trifluoroacetate manufacturer , order VTP-27999 2,2,2-trifluoroacetate , high purity VTP-27999 2,2,2-trifluoroacetate

Online Inquiry for:

      Fill out the information below

      • Size:Qty: - +

      * Required Fields

                                      Result: